ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,463.54
      0.08%
      US Tech 100
      18,493.20
      -0.14%
      Dow Jones
      40,539.93
      -0.12%
      Brent Oil
      78.88
      -0.33%
      Bitcoin
      66,332.11
      -0.74%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Gilead Sciences Inc (GILD) Quote

      Gilead Sciences Inc

      Gilead Sciences Inc (GILD)

      DMG Mori AG
      DMG Mori AG
      DMG Mori AG
      DMG Mori AG
      Guild Esports Plc
      77.73
      0.72
      (0.93%)
      Closed July 29 4:00PM
      Delayed by 15 minutes
      77.5092
      -0.2208
      (-0.28%)
      After Hours: 7:55PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      77.5092
      Bid
      77.30
      Ask
      77.73
      Volume
      4,571,065
      76.81 Day's Range 77.98
      62.07 52 Week Range 87.865
      Market Cap
      96.565B
      Previous Close
      77.01
      Open
      77.12
      Last Trade
      1
      @
      77.73
      Last Trade Time
      Financial Volume
      $ 354,056,040
      VWAP
      77.4559
      Average Volume (3m)
      7,326,822
      Shares Outstanding
      1,245,853,209
      Dividend Yield
      3.92%
      PE Ratio
      17.09
      Earnings Per Share (EPS)
      4.55
      Revenue
      27.12B
      Net Profit
      5.67B

      About Gilead Sciences Inc

      Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.gilead.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Gilead Sciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GILD. The last closing price for Gilead Sciences was $77.01. Over the last year, Gilead Sciences shares have traded in a share price range of $ 62.07 to $ 87.865.

      Gilead Sciences currently has 1,245,853,209 shares outstanding. The market capitalization of Gilead Sciences is $95.94 billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 17.09.

      Gilead Sciences (GILD) Options Flow Summary

      GILD Options Flow

      Overall Flow

      Bullish

      Net Premium

      2M

      Calls / Puts

      1,333.33%

      Buys / Sells

      21.21%

      OTM / ITM

      13.16%

      Sweeps Ratio

      0.00%

      GILD Latest News

      More News

      FeaturedCannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA

      12 hours ago

      Sodexo finalise avec succès le refinancement de son crédit bancaire syndiqué assorti d’une clause de durabilité pour un montant de 1,75 milliard d’euros

      Sodexo finalise avec succès le refinancement de son crédit bancaire syndiqué assorti d’une clause de durabilité pour un montant de 1,75 milliard d’euros Issy-les-Moulineaux, 25 juillet 2024 –...

      July 25 2024
      UK Regulatory

      Sodexo successfully completes €1.75bn refinancing of the Sustainability linked Syndicated Revolving Credit Facility

      Sodexo successfully completes €1.75bn refinancing of the Sustainability linked Syndicated Revolving Credit Facility Issy-les-Moulineaux, July 25, 2024 – Sodexo announces that it has amended and...

      July 25 2024
      UK Regulatory

      Sodexo successfully completes €1.75bn refinancing of the Sustainability linked Syndicated Revolving Credit Facility

      Issy-les-Moulineaux, July 25, 2024 – Sodexo announces that it has amended and extended its core Syndicated Revolving Credit Facility for a further 5 years to July 2029 with two additional one-year...

      July 25 2024
      GlobeNewswire Inc.

      Sodexo is pleased to announce the simplification of its ownership structure and payment of an interim dividend of €6.24 per share

      Sodexo is pleased to announce the simplification of its ownership structure and payment of an interim dividend of €6.24 per share Issy-les-Moulineaux, July 23, 2024   Sale of Sodexo's 100% owned...

      July 23 2024
      UK Regulatory

      Sodexo is pleased to announce the simplification of its ownership structure and payment of an interim dividend of €6.24 per share

      Issy-les-Moulineaux, July 23, 2024   Sale of Sodexo's 100% owned subsidiary Sofinsod to Bellon SA for 918 million euros, simplifying the ownership structure of Sodexo, and monetizing an illiquid...

      July 23 2024
      GlobeNewswire Inc.

      Sodexo est heureux d’annoncer la simplification de la structure actionnariale du groupe et le versement d’un acompte sur dividende de 6,24€ par action

      Sodexo est heureux d’annoncer la simplification de la structure actionnariale du groupe et le versement d’un acompte sur dividende de 6,24€ par action Issy-les-Moulineaux, 23 juillet 2024 Cession...

      July 23 2024
      UK Regulatory

      Sodexo - Interim report on liquidity contract as of June 30, 2024

      Sodexo - Interim report on liquidity contract as of June 30, 2024 Regulated information Issy-les-Moulineaux, July 10, 2024 Interim report on liquidity contract as of June 30, 2024 Under the...

      July 10 2024
      UK Regulatory

      Sodexo - Bilan semestriel du contrat de liquidité au 30 juin 2024

      Sodexo - Bilan semestriel du contrat de liquidité au 30 juin 2024 Information réglementée Issy-les-Moulineaux, le 10 juillet 2024 Bilan semestriel du contrat de liquidité au 30 juin 2024 Au...

      July 10 2024
      UK Regulatory

      Sodexo - Déclaration mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 30 juin 2024

      Sodexo - Déclaration mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 30 juin 2024 Information réglementée Issy-les-Moulineaux, 3 juillet...

      July 03 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      14.81926.6297977713672.6978.2970.78648822074.9793581CS
      48.849212.888435770568.6678.2966.01597654871.46931593CS
      1212.729219.64989194264.7878.2962.07732682267.95285345CS
      26-2.1408-2.6877589453979.6580.00562.07736466070.02474739CS
      520.81921.0681966358176.6987.86562.07670846673.86607941CS
      1567.259210.333380782970.2589.7457.165717526371.61970041CS
      2609.419213.833455720468.0989.7456.56836199470.35527168CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      TWOU2U Inc
      $ 2.70
      (116.00%)
      		139.18M
      LIPOLipella Pharmaceuticals Inc
      $ 0.8576
      (112.22%)
      		194.69M
      NIPGNIP Group Inc
       16.50
      (82.93%)
      		7.04M
      TIVCTivic Health Systems Inc
      $ 0.7049
      (55.95%)
      		106.15M
      ISPOInspirato Inc
      $ 5.15
      (47.99%)
      		6.24M
      CGTXCognition Therapeutics Inc
      $ 1.32
      (-44.30%)
      		26.32M
      GRIGRI Bio Inc
      $ 0.8334
      (-33.86%)
      		1.14M
      CEROCERo Therapeutics Holdings Inc
      $ 0.1817
      (-29.02%)
      		8.28M
      PRSTPresto Technologies Inc
      $ 0.0499
      (-26.51%)
      		29.32M
      TGLTreasure Global Inc
      $ 1.40
      (-24.32%)
      		80.79k
      NVDANVIDIA Corporation
      $ 111.59
      (-1.30%)
      		248.03M
      LIPOLipella Pharmaceuticals Inc
      $ 0.8576
      (112.22%)
      		194.69M
      SQQQProShares UltraPro Short QQQ
      $ 9.05
      (-0.55%)
      		152.03M
      TWOU2U Inc
      $ 2.70
      (116.00%)
      		139.18M
      TSLATesla Inc
      $ 232.10
      (5.60%)
      		129.2M

      GILD Discussion

      View Posts
      TechandBio TechandBio 7 hours ago
      Adding shares and calls under $80..00

      HIV Cure Vaccine is a big deal data is incredible flawless. Oncology pipeline is building nicely.



      $GILD
      $GILD
      👍️0
      midastouch017 midastouch017 12 hours ago
      Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

      https://finance.yahoo.com/news/compugen-announces-fda-clearance-ind-110000034.html

      FDA clearance triggers a $30 million milestone payment from Gilead
      👍️0
      Monksdream Monksdream 1 day ago
      GILD under $100
      👍️0
      TechandBio TechandBio 4 days ago
      Target is $100-$120 by Q2 2025

      $GILD
      👍️0
      TechandBio TechandBio 5 days ago
      HIV Prevention CURE Shot 2x a year

      Great growing oncology pipeline!

      my $80 vertical Calls from last week are looking golden!

      $GILD
      👍️0
      north40000 north40000 1 month ago
      https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602784

      "Gilead plans to share new preclinical data for an oral GLP-1 at the upcoming American Diabetes Association conference starting June 21… The asset, dubbed GS-4571, has previously demonstrated 5% to 8% weight loss in monkeys in 28 to 30 days…"
      👍️0
      north40000 north40000 1 month ago
      How about oral GLP-1 news? CNBC-TV AH today. Portal Innovations CEO interview.
      👍️0
      jondoeuk jondoeuk 2 months ago
      There is barely any move on this news. Seems the market had already written it off. O'Day needs to go, they need to rebuild in areas they have expertise in and refocus in oncology.
      👍️0
      jondoeuk jondoeuk 2 months ago
      A double whammy https://www.oncologypipeline.com/apexonco/asco-2024-full-evoke-01-result-adds-gileads-trodelvy-problems
      👍️0
      jondoeuk jondoeuk 2 months ago
      They guided that a third of revenues will be from oncology by 2030...! https://www.businesswire.com/news/home/20240530516266/en/Gilead-Provides-Update-on-Phase-3-TROPiCS-04-Study
      👍️0
      jondoeuk jondoeuk 2 months ago
      ''Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors.'' https://www.nature.com/articles/s43018-024-00768-3

      https://medicalxpress.com/news/2024-05-cancer-optimal-cells.html
      👍️0
      jondoeuk jondoeuk 2 months ago
      The oNKo-Innate team, along with scientists at Kite, have just published a research article https://onlinelibrary.wiley.com/doi/10.1002/cti2.1507

      Optimised manufacturing dramatically improves lentiviral transduction efficiency of primary human NK cells. The field has progressed greatly with CAR transduction rates in human NK cells (it was ~5% just a few years ago). The oNKo-Innate R&D team were able to raise CAR transduction efficiency to ~80%. After testing various NK cell sources, they conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make PB-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

      ''No doubt CAR-NK cells have faced several challenges in oncology settings, and we hope our new findings assist researchers in addressing some of these challenges while also improving the potential for CAR-NK cell therapies in treating autoimmune disease such as lupus'' said Nicholas Huntington, PhD, oNKo-innate's CSO.
      👍️0
      jondoeuk jondoeuk 3 months ago
      The management has been substandard for many years https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels and https://www.fiercepharma.com/pharma/gilead-writes-24b-trodelvy-ceo-underscores-time-focused-execution
      👍️0
      jondoeuk jondoeuk 4 months ago
      IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve
      👍️0
      jondoeuk jondoeuk 4 months ago
      Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.
      👍️0
      jondoeuk jondoeuk 4 months ago
      Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf
      👍️0
      jondoeuk jondoeuk 4 months ago
      I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and
      👍️0
      jondoeuk jondoeuk 4 months ago
      Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568
      👍️0
      Monksdream Monksdream 6 months ago
      GILD new 52 week high
      👍️0
      jondoeuk jondoeuk 8 months ago
      Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

      It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.
      👍️0
      jondoeuk jondoeuk 9 months ago
      Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

      There have been a number of these over the years, but nothing seems to come of them
      👍️0
      jondoeuk jondoeuk 9 months ago
      The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

      If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.
      👍️0
      Greedy G Greedy G 11 months ago
      ~bought 9/22 $80 calls .08c
      👍️0
      jondoeuk jondoeuk 1 year ago
      Q1 results https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171789595
      👍️0
      DewDiligence DewDiligence 1 year ago
      Why is an oral prodrug of Remdesivir anything to get excited about?
      👍️0
      jondoeuk jondoeuk 1 year ago
      Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-details-promising-early-covid-223448308.html
      👍️0
      jondoeuk jondoeuk 1 year ago
      Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma

      What's big is that the trial reached five year maturity instead of just the number of deaths. Looking at it, more than 210 of the 359 (58%) are still alive at five years compared to 43% in ZUMA-1 (3L+). Sure, these were healthier patients, but the CR rate was more double (65% vs. 32%) against the standard of care. So, treatment works better in healthier patients. ZUMA-23 in 1L (against R-CHOP) is ongoing.

      The next question is whether treating healthier patients with multiple myeloma (if they can resolve supply issues with auto) can (significantly) improve PFS.
      👍️0
      fink fink 2 years ago
      Christmas sell off over, last day to lock in any paper tax loss. LOL

      Who’s losing money here?

      I think we start the trend back up into Q1
      👍️0
      fink fink 2 years ago
      It wants $90.
      I got a sell order in @88, but think it will continue up.
      Gilead is moving away from HIV and more into this cancer thingy.

      That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too

      Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price
      👍️0
      PennyPusher786 PennyPusher786 2 years ago
      It's at a 3 year high
      👍️0
      fung_derf fung_derf 2 years ago
      Very funny that you posted this to me. I couldn't recall, but knew there were a couple of you who followed me over here. It has had a pretty nice month.

      I_luv_cydy

      Re: fung_derf post# 3875

      Tuesday, May 19, 2020 2:32:23 PM

      Post#
      3878
      of 4839
      Fung: Why do you suppose GILD keeps dropping? I'm a shareholder for a while.
      👍️0
      fink fink 2 years ago
      Nice to see GILD over $80

      Wonder if I should trim some? It’s been eating chit pie for some time.
      Still don’t see why the spike.
      👍️0
      jondoeuk jondoeuk 2 years ago
      Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers https://www.businesswire.com/news/home/20221020005633/en/Kite-and-Refuge-Biotechnologies-Announce-Exclusive-License-Agreement-for-Investigational-Gene-Expression-Platform-for-Blood-Cancers

      Some preclinical data from Refuge Bio https://jitc.bmj.com/content/8/Suppl_3/A86.2 https://jitc.bmj.com/content/9/Suppl_2/A162 https://jitc.bmj.com/content/9/Suppl_2/A164 https://jitc.bmj.com/content/8/Suppl_3/A458.2
      👍️0
      Zeppo Zeppo 2 years ago
      Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.
      👍️0
      DewDiligence DewDiligence 2 years ago
      GILD details why the purportedly-positive Trodelvy data from Mar 2022 weren’t:

      https://www.businesswire.com/news/home/20220603005437/en The study met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death (median PFS 5.5 vs. 4 months; HR: 0.66; 95% CI: 0.53-0.83; P<0.0003). The first interim analysis of the key secondary endpoint of overall survival (OS) demonstrated a trend in improvement. In this context, a “trend in improvement” means non-statsig. OS could conceivably turn statsig in a later data cut, but that’s pretty unlikely.

      The viewpoint in #msg-158260565 (from 2020) has not changed.
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      59.77 ? -1.79 (-2.91%)
      Volume: 10,483,423 @04/29/22 7:42:23 PM EDT
      Bid Ask Day's Range
      59.53 60.0 59.27 - 62.06
      GILD Detailed Quote
      👍️0
      jondoeuk jondoeuk 2 years ago
      ZUMA-11. Improved CAR-T responses with 4-1BB agonist utomilumab added to axi-cel. The cells were more of central and effector phenotype. No (S)AE concerns.




      👍️0
      jondoeuk jondoeuk 2 years ago
      Link to the audio recording https://investors.gilead.com/events/event-details/gilead-sciences-oncology-deep-dive
      👍️0
      jondoeuk jondoeuk 2 years ago
      Oncology Deep Dive https://investors.gilead.com/static-files/332d0c81-fa18-44fa-82d3-babf96ca12d0

      https://endpts.com/with-more-than-30-oncology-partners-gilead-lays-out-its-2030-vision-of-20-new-approvals/
      👍️0
      jondoeuk jondoeuk 2 years ago
      ZUMA-12 https://www.nature.com/articles/s41591-022-01731-4

      The CR rate was higher than standard frontline chemo, with just a single treatment vs. six cycles over about four months.

      No reason to think long-term curve won't flatten like ZUMA-1 (which was post ~two years).

      PDUFA date (for 2nd line) is April 1.
      👍️0
      mick mick 2 years ago
      GILD News: Gilead price target slashed at Barclays following new Trodelvy data 03/10/2022 05:38:07 AM
      GILD News: Current Report Filing (8-k) 03/07/2022 03:31:07 AM
      GILD News: Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer 03/07/2022 03:30:00 AM
      GILD News: Robert W. Baird Sticks to Their Hold Rating for Gilead Sciences (GILD) 03/03/2022 12:10:51 AM
      GILD News: Jefferies Thinks Gilead Sciences’ Stock is Going to Recover 03/02/2022 03:35:55 AM
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      58.39 ? 0.47 (0.81%)
      Volume: 13,007,627 @03/11/22 7:41:31 PM EST
      Bid Ask Day's Range
      58.2 58.4 57.955 - 59.185
      GILD Detailed Quote
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      61.33 ? 0.22 (0.36%)
      Volume: 9,751,206 @02/15/22 4:17:32 PM EST
      Bid Ask Day's Range
      61.15 61.33 60.97 - 61.515
      GILD Detailed Quote
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      63.9 ? -1.49 (-2.28%)
      Volume: 12,392,843 @02/04/22 7:58:42 PM EST
      Bid Ask Day's Range
      63.8 64.0 63.8722 - 65.61
      GILD Detailed Quote
      👍️0
      DewDiligence DewDiligence 2 years ago
      GILD owes ViiV* $1.25B+_3% royalty on_US Biktarvy sales, as a result of a patent settlement:

      https://www.gsk.com/en-gb/media/press-releases/gsk-announces-settlement-between-viiv-healthcare-and-gilead-sciences/

      The 3% royalty is a pretty big deal since Biktarvy’s had annualized US sales of $8.4B(!) in 4Q21.

      * ViiV is a JV comprised of: GSK (76.5%); PFE (13.5%); and Shionogi (10%).
      👍️0
      DewDiligence DewDiligence 2 years ago
      GILD 4Q21 results…

      PR:
      https://investors.gilead.com/static-files/107ab0e3-735c-4760-882f-c3647ea97ce2

      CC slides:
      https://investors.gilead.com/static-files/afa262c5-7eed-4944-81f5-3c2d09489d1b
      👍️0
      mick mick 3 years ago
      https://www.otcmarkets.com/stock/GILD
      👍️0
      DewDiligence DewDiligence 3 years ago
      GILD vs BMY in LBCL CAR-T—who has the edge?

      https://www.fiercepharma.com/pharma/bristol-myers-squibb-breyanzi-gilead-yescarta-lock-horns-car-t-therapy-earlier-lymphoma

      Both Yescarta and Breyanzi are poised to take share from stemcell transplants.
      👍️0
      mick mick 3 years ago
      https://www.otcmarkets.com/stock/GILD
      👍️0
      dhbuzz dhbuzz 3 years ago
      GILD and MTNB have been working on ORAL remdesivir ,results to date look outstanding ,if this is green lighted by FDA,should really give GILD a SP jump as well as MTNB

      GLTA
      👍️0

      Your Recent History

      NASDAQ
      GILD
      Gilead Sciences
      Delayed Upgrade Clock